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Guest Editorial
The 3rd International Symposium on Kallikreins
and Kallikrein-Related Peptidases
The 3rd International Symposium on Kallikreins and Kalli-
krein-Related Peptidases (IKS 2009) took place from August
30 to September 2, 2009, in Munich, Germany. Pioneering
work of H. Kraut, E.-K. Frey, and E. Werle conducted here
in Munich in the first half of the last century led to the
identification of tissue kallikrein as the proteolytic enzyme
liberating the vasoactive peptide kallidin from its substrate
low-molecular-weight kininogen. As we know today, tissue
kallikrein (KLK1) is just one member of the human kalli-
krein-related peptidase family (for reviews see, e.g., Lund-
wall et al., 2006; Lundwall and Brattsand, 2008; Sot-
iropoulou et al., 2009). This family encompasses 15 KLK
genes located on chromosome 19q13.4 and constitutes the
largest cluster of serine proteases in the human genome.
KLKB1, the gene encoding plasma kallikrein, which is more
closely related to blood coagulation factor XI than to KLK1,
is located on a different chromosome, 4q35.
In contrast to KLK1, the other members of the KLK fam-
ily display weak or no kininogenase activity. KLK1 thus is
the only ‘true’ tissue kallikrein, whereas the kallikrein-relat-
ed peptidases target other substrates and fulfill other func-
tions. The highly homologous members KLK1, KLK2
(glandular kallikrein), and KLK3 (prostate-specific antigen,
PSA) form a subgroup within the KLK family (named ‘clas-
sical’ KLKs) sharing the so-called kallikrein-loop, a unique
11-residue insertion in the 99-loop of serine proteases that
lies just above the active-site cleft and strongly impacts
enzyme/substrate interactions. Whereas KLK1, -2, and -3
have been known for a long time, the other members of the
KLK family were identified rather late in the 1990s. All
KLKs are produced as single-chain pre-pro-proteases con-
taining a single chymotrypsin- or trypsin-like catalytic do-
main. After secretion as inactive zymogens, the KLKs are
extracellularly activated by removal of their short propep-
tides. The majority of these kallikrein-related peptidases
prefer, like trypsin, basic P1 residues, whereas few mem-
bers cleave similar to chymotrypsin or with a mixed P1
specificity.
The identification of the KLK gene cluster has boosted
intensive research focusing on the analysis of the
(patho)physiological functions of the KLK proteases. More
than 150 participants from 20 different countries (14 Euro-
pean countries, USA, Canada, Australia, Japan, Mexico, and
Brazil) attended the symposium in Munich that was sup-
ported in particular by the German Research Association
(DFG), the International Union for Biochemistry and Molec-
ular Biology, and the E.K. Frey-E. Werle Foundation.
The research progress in the KLK field presented and dis-
cussed at the symposium is particularly exemplified by the
work of the recipients of the three awards presented by the
E.K. Frey-E. Werle Foundation. The ‘Commemorative Gold
Medal’ was given to Michael Blaber, mainly for his funda-
mental findings on the involvement of KLK6 in neurological
disorders and the elucidation of activation relationships with-
in the KLK family and with the thrombostasis system. In
2002, Blaber and colleagues solved the crystal structure of
the first mature, active human kallikrein-related peptidase,
KLK6, which is abundantly expressed in the central nervous
system. At the same time, the structure of pro-KLK6 was
reported displaying a completely closed specificity pocket
and other striking structural differences. Comparison of both
structures allowed a detailed analysis of rearrangements
occurring upon proteolytic activation. Meanwhile, the struc-
tures of several other human KLK proteases, i.e., KLK1, -3,
-4, -5, and -7, have been published.
In normal and malignant tissues, members of the kallikrein
family and various other endopeptidases are coexpressed,
raising the possibility that KLKs can participate in proteo-
lytic cascades. To analyze the activation of the human pro-
KLKs, Blaber and coworkers established a high-throughput
system allowing characterization of KLK propeptide cleav-
age. For this, all propeptides of the KLK protease family
were individually fused to a soluble, protease-resistant carrier
protein and these fusion proteins incubated with mature
KLKs or other active proteases revealing a series of potential
activating pairs (for a review see Blaber et al., 2010). Other
findings emphasize that KLKs are integrated within proteo-
lytic networks. Several trypsin-like KLKs have, e.g., been
shown to be potent activators of the zymogens of the serine
protease urokinase-type plasminogen activator (uPA) as well
as the metalloproteases meprin a and b. Interestingly, in a
complementary setting, meprin b cleaves pro-KLK7 two
amino acids upstream its activation cleavage site. Such pro-
cessing, although leaving the zymogen inactive, can prime
pro-KLK7 towards further activation by endoproteases and,
potentially, exoproteases as well (Ohler et al., 2010).
Many members of the KLK family represent biomarkers,
particularly in prostate, ovarian, colon, and breast cancer,
either regarding prediction of the course of the disease (prog-
nosis) or response to therapy. Andreas Scorilas received the
‘E.K. Frey-E. Werle Promotion Prize’ for his innovative
investigations on the development of highly sensitive quan-
titative assays for biomarkers, particularly KLKs, and the
evaluation of their clinical relevance. In the present highlight
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issue, effects on KLK5 gene expression in prostate cancer
cells upon treatment with chemotherapeutic agents are
described (Mavridis et al., 2010). Analysis of mRNA expres-
sion of the KLK gene family is complex, as alternative splic-
ing is frequent. Increased expression of an alternatively
spliced KLK3 variant was observed in prostate cancer
(Whitbread et al., 2010). In addition to mRNA quantification
and determination of protein levels by ELISA, expression of
KLK proteases within normal and malignant tissues has been
extensively analyzed by immunohistochemical methods (see,
e.g., Gabril et al., 2010, and Seiz et al., 2010). To investigate
the levels of kallikrein-related peptidase activity in ascitic
fluids of ovarian cancer patients, an irreversible inhibitor of
trypsin-like proteases, hooked to biotin via a chemical linker,
was used to precipitate proteases with streptavidin-coated
magnetic beads (Oikonomopoulou et al., 2010a). Interesting-
ly, only low levels of active KLK enzymes relative to the
total amounts determined by ELISA were present in these
ascitic fluids. One possible explanation is that active KLK
proteases rapidly form complexes with natural inhibitors also
present in ascitic fluids. Nevertheless, as over- or de novo
expression of KLKs is often associated with poor patient
outcome, these proteases certainly represent attractive targets
for tumor therapy. Although still a matter of debate, even
KLK3 (prostate-specific antigen, PSA), which at present is
clinically used as a diagnostic and monitoring marker, could
be a candidate for cancer treatment by inhibiting its proteo-
lytic activity (LeBeau et al., 2010). The use of engineered
sunflower trypsin inhibitors to target KLK4 or KLK14
(Swedberg et al., 2010) or other scaffolds such as ecotin
(Stoop et al., 2010) could allow a tight control of proteolytic
activity in cancer patients. Furthermore, cyclic peptides were
developed to inhibit the proteolytic activity of KLK2 (Hekim
et al., 2010). A novel approach to regulate KLK overpro-
duction is the use of microRNAs, small RNAs that do not
code for proteins but function by controlling the expression
of other genes (White et al., 2010).
In addition to their contribution to the degradation of
extracellular matrix proteins and their supposable involve-
ment in inflammatory pathways (Sotiropoulou and Pampa-
lakis, 2010), it is now clear that certain KLKs serve as
signaling molecules controlling cell functions through spe-
cific membrane receptors, the protease-activated receptors
(PARs). The signals, induced by proteolytic cleavage of the
receptors, modulate processes including platelet aggregation,
vascular relaxation, cell proliferation, cytokine release, and
inflammation. Katerina Oikonomopoulou, recipient of the
‘E.K. Frey–E. Werle Young Investigator Award 2009’, dem-
onstrated in cell model systems that KLK5, -6, and -14 can
activate PAR1, -2, and -4 to different extents (reviewed in
Oikonomopoulou et al., 2010b). Together with independent
work by other groups, these results suggest that some KLK
proteases could be major modulators of PAR-mediated sig-
naling in inflammatory diseases and/or cancer.
Although the emphasis of the IKS 2009 symposium in
Munich was on the analysis of the (patho)physiological func-
tions of the ‘new’ kallikreins KLK4–KLK15, it offered a
series of presentations on the progress in research concerning
the ‘classical’ kallikreins KLK1–KLK3 as well. This is
reflected by several articles in the present highlight issue,
including a review on the role of KLK1 in various types of
diseases and wound healing (Chao et al., 2010), the pres-
entation of a protein network linking the kallikrein-kinin and
renin-angiotensin systems developed by employing three-
dimensional protein-protein interaction databases (Stoka and
Turk, 2010), and the analysis of transgenic mice expressing
rat tonin, the homolog of KLK2, in the brain (Cardoso et al.,
2010). In the case of KLK1 and KLK8, knockout mouse
models have also been utilized to elucidate their physiolog-
ical functions. Interestingly, analyses of KLK8-/- mice indi-
cate that this protease can also have functions in the brain
as well as in the skin (see Yoshida, 2010).
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